March 26, 2012
Results from a small study of 62 co-infected people treated with Incivek showed that 74% had undetectable viral loads at 12 weeks after stopping their hepatitis C treatment, compared to 45% on pegylated interferon + ribavirin alone. About one-quarter were not on HIV treatment (13) while most (47) were taking Atripla or boosted Reyataz (atazanavir) + Truvada (Viread/tenofovir + Emtriva/emtricitabine).
Incivek + pegylated interferon + ribavirin was given for the first 12 weeks, and then interferon + ribavirin only for the next 36 weeks. The average age of the participants was 45, and only 15% were women. Most people had HCV viral loads above 800,000, while 10% had advanced liver fibrosis. Nearly 68% had HCV genotype 1a while the others had 1b, both of which are more difficult to treat types.
The following chart describes 12-week post-treatment undetectable HCV viral loads (T/PR = Incivek + pegylated interferon + ribavirin):
|No HIV meds||Atripla||Reyataz||Total|
|12 wks post||71%||33%||69%||50%||80%||50%||74%||45%|
The following details should be noted about this study:
Larger studies will be conducted. These will include people new to HCV treatment, people who rebounded after HCV treatment, partial responders, and non-responders.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|